Pharmaceutical Industry Analysis: Market Research, Survey, Growth & Reports

Indian Pharma Sector

India is among the top six global pharmaceutical producers in the world. Indian vaccines are exported to 150 countries. India produces 40-70 per cent of the WHO demand for DPT & BCG and 90 per cent of measles vaccine. Approximately 70 per cent of the patients in developing countries receive Indian medicines through NGOs like The Clinton Foundation, Bill & Melinda Gates Foundation, Doctors Without Borders, the UNCTAD etc.

Presently there are 10,500 manufacturing units and over 3,000 pharma companies in India, growing at an exceptional rate. India has about 1,400 WHO GMP approved manufacturing units. India has been accredited with approximately 1,105 CEPs, more than 950 TGA approvals and 584 sites approved by the USFDA. Globally more than 90 per cent of formulations approvals for Anti-retroviral (ARVs), Anti-tubercular & Anti-malarial (WHO pre-qualified) have been granted to India.Manufacturing costs in India are approximately 35-40 per cent of those in the US due to low installation and manufacturing costs. India ranks amongst the top global generic formulation exporters in volume terms.

India's exports of pharma and drugs stood at US$ 16.8 bn.India exports all forms of pharmaceuticals from APIs to formulations, both in modern medicine and traditional Indian medicines.The country's pharmaceutical industry accounts for about 1.4 per cent of the global pharmaceutical industry in value terms and 10 per cent in volume terms.

The Government of India has announced a host of measures to create a facilitating environment for the Indian pharmaceutical industry. The policies of the Government of India are aimed at building more hospitals, boosting local access to healthcare, improving the quality of pharmaceuticals and improving the quality of medical training. The Government of India is committed to setting up robust healthcare and delivery mechanisms. India is well placed to become one of the major drivers in providing healthcare to all while controlling the ever-increasing healthcare spend of both developed and developing nations.

 

Indian Pharma Sector

indian pharma market
  • As per 'Pharma Vision 2020', the Government of India aims to make India a global leader in end-to-end drug manufacturing.
  • Manufacturing costs in India are approximately 35-40 per cent of those in the US due to low installation and manufacturing costs.
  • Pharmaceutical exports from India have grown at a CAGR of 21 per cent over the last decade.
  • Indian vaccines are exported to 150 countries.
  • The projected human resource requirement in the Indian pharma sector is estimated to be about 21,50,000 by 2020

Pharma Manufacturing & Patents

  • India is home to 10,500 manufacturing units and over 3,000 pharma companies.
  • India accounts for 36.9 per cent (3,411) of the 9,296 Drug Master Files (DMFs) filed with the USA, which is the highest outside of the USA (as on December 31, 2013).
  • Higher spending on R&D, owing to products patents have made India a major destination for generic drug manufacturing.
  • India has been accredited with approximately 1,105 CEPs, more than 950 TGA approvals and 584 sites registered by the USFDA.
  • Following the introduction of product patents, several multinational companies are expected to launch patented drugs in India.

Exports

  • India's pharma exports stood at US$ 15 billion in 2013-14.
  • Pharmaceutical exports from India have grown at a CAGR of 21 per cent over the last decade.
  • India ranks fourth in terms of the total pharma market share in the Asia Pacific.
  • Approximately 70 per cent of the patients in developing countries receive Indian medicines through NGOs like The Clinton Foundation, Bill & Melinda Gates Foundation, Doctors Without Borders, the UNCTAD etc.

Household Spend & Growth in Rural India

  • The Government of India is committed to setting up robust healthcare and delivery mechanisms.
  • Due to increasing population and income levels, demand for high-end drugs in India is expected to reach US$ 8 billion by 2015.
  • Expenditure on pharmaceuticals is likely to increase to over 40 per cent of the total spending on healthcare by households by 2015.
  • With 70 per cent of India's population residing in rural markets, various pharma companies are investing in the distribution network in rural areas.
IBEF logo